{
  "abstract": "Background: Allergen immunotherapy (AIT) may modify allergic respiratory disease, but its association with progression and remission in routine practice remains uncertain.\n\nMaterials and Methods: We emulated a target trial in a single‐center retrospective cohort at AlergiaMx, Mexico City, using data from 2020 to 2025. We compared sublingual allergen immunotherapy initiation within a 14‐day grace period with non‐initiation among AIT‐eligible patients. Follow‐up extended up to 36 months, and propensity‐score overlap weighting addressed baseline confounding.\n\nResults: Among 2,713 patients, 1,971 initiated AIT and 742 did not. Weighted disease worsening was 46.3% versus 63.6% (relative risk [RR] 0.73, 95% confidence interval [CI] 0.65–0.82), and sustained progression was 8.4% versus 17.0% (RR 0.49, 95% CI 0.35–0.69). At 36 months, clinical remission was 47.0% versus 18.3% (RR 2.57, 95% CI 1.93–3.43), and treatment‐associated remission was 31.7% versus 5.8% (RR 5.44, 95% CI 3.23–9.16). Longitudinal differences favored AIT for asthma control, quality of life, and fractional exhaled nitric oxide.\n\nDiscussion: AIT initiation was associated with less worsening, greater remission, and favorable clinical and inflammatory trajectories over 36 months. These observational findings do not establish a causal disease‐modifying effect; residual confounding and differential follow‐up remain possible.",
  "abstract_shown": true,
  "affiliations": [
    "AlergiaMx Mexico City Mexico",
    "Facultad Mexicana de Medicina Universidad La Salle México Mexico City Mexico"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Víctor Gonzalez‐Uribe",
      "orcid": "0000-0001-9053-7108"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Sebastian Moreno‐Castro",
      "orcid": "0009-0005-7705-6162"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Viviana Cardoso‐Perez",
      "orcid": "0009-0006-0710-4998"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Diego A Mares‐Mateos",
      "orcid": "0009-0002-8197-7077"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Mariel Paez‐Reyes",
      "orcid": "0009-0006-7640-3860"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Jimena Prieto‐Gomez",
      "orcid": "0009-0000-7455-002X"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Ricardo Martinez‐Tenopala",
      "orcid": "0000-0001-5175-3828"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Paola de Baro Alvarez",
      "orcid": "0009-0006-8519-2030"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1kx4zt6w8sjfw.bib",
  "cited_by": 0,
  "doi": "10.1002/iid3.70569",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710663/",
  "id": "1kx4zt6w8sjfw",
  "issns": [
    "2050-4527"
  ],
  "landing_url": "https://doi.org/10.1002/iid3.70569",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2723|Allergic Rhinitis and Sensitization"
    ]
  ],
  "openalex": "W7223928432",
  "pdf_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/iid3.70569",
  "pmcid": "PMC13710663",
  "pmid": "42934766",
  "published": "2026-10-26",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/1kx4zt6w8sjfw.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:35Z",
      "native_id": "PMC13710663",
      "source": "pmc",
      "url": "https://doi.org/10.1002/iid3.70569"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2723|Allergic Rhinitis and Sensitization",
      "subfield": "immunology"
    }
  ],
  "title": "Allergen Immunotherapy and 36‐Month Allergic Respiratory Disease Trajectories: A Target‐Trial",
  "title_text": "Allergen Immunotherapy and 36‐Month Allergic Respiratory Disease Trajectories: A Target‐Trial",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:35Z",
  "url": "https://research.draconitic.com/paper/1kx4zt6w8sjfw",
  "venue": "Immunity, Inflammation and Disease",
  "versions": []
}